Effect of Proanthocyanidins from Grape Seed Extract on Benign Prostatic Hyperplasia

被引:0
|
作者
Iannuzzo, Fortuna [1 ]
Schiano, Elisabetta [2 ]
Maisto, Maria [3 ]
Schettino, Anna [4 ]
Marigliano, Noemi [4 ]
Saviano, Anella [4 ]
Abo Mansour, Adel [5 ]
Iqbal, Asif Jilani [4 ,6 ]
Maione, Francesco [4 ]
Tenore, Gian Carlo [3 ]
Novellino, Ettore [7 ]
机构
[1] Univ Chieti Pescara G Annunzio, Dept Pharm, I-66100 Chieti, Italy
[2] Inventia Biotech Healthcare Food Res Ctr Srl, Str Statale Sannit KM 20-700, I-81020 Caserta, Italy
[3] Univ Naples Federico II, Dept Pharm, Via Domenico Montesano 49, I-80131 Naples, Italy
[4] Univ Naples Federico II, Sch Med & Surg, Dept Pharm, ImmunoPharmaLab, Via Domenico Montesano 49, I-80131 Naples, Italy
[5] King Khalid Univ, Coll Appl Med Sci, Dept Clin Lab Sci, Abha 62521, Saudi Arabia
[6] Univ Birmingham, Coll Med & Hlth, Dept Cardiovasc Sci, Birmingham B15 2TT, England
[7] Univ Cattolica Sacro Cuore, Fac Med & Surg, I-00168 ROME, Italy
关键词
benign prostatic hyperplasia; grape seeds; proanthocyanidins; <italic>Vitis vinifera</italic>; TESTOSTERONE; DIHYDROTESTOSTERONE; PROLIFERATION; INFLAMMATION; INHIBITORS;
D O I
10.3390/nu17010073
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background/Objectives: Benign prostatic hyperplasia (BPH) is one of the most common chronic diseases affecting the urinary tract that occurs mainly in men over 40 years of age. Among the natural therapies, proanthocyanidins (PACs), which can treat a wide range of immune-mediated inflammatory diseases (IMIDs), have been shown to play an important role in the treatment of pathologies concerning prostate health. In this regard, the present study aimed to evaluate the different bioactivities of a grape seed extract (GSE), rich in polymeric PACs, and its version processed under alkaline conditions (ATGSE), characterized by a higher content of oligomeric PACs, in an animal model of BPH induced by subcutaneous injection of testosterone (1 mg/mouse). Methods: These latter were divided into a control group (vehicle, olive oil), a BPH group (testosterone 1 mg/mouse), and four treatment groups treated with GSE (500 mg/kg) and ATGSE (125, 250, 500 mg/kg) by oral gavage. At the experimental endpoint (4 weeks), hematological and biochemical analyses of blood and tissues were performed. Results: Data showed that oral administration of ATGSE (250 mg/kg) was significantly more effective than GSE in reducing prostate (p <= 0.0001) and seminal vesicle (p <= 0.0001) weight. Moreover, ATGSE exhibited enhanced effectiveness in significantly reducing PSA levels (p <= 0.0001 vs. GSE) and the expression of key pro-inflammatory cyto-chemokines in prostate and seminal vesicles homogenates. Conclusions: These findings pave the way for the clinical application of ATGSE as a nutraceutical and/or functional food.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] Benign prostatic hyperplasia
    Hernandez, Sarelis Infante
    Rivas, Juan Gomez
    Sierra, Jesus Moreno
    MEDICINA CLINICA, 2024, 163 (08): : 407 - 414
  • [42] Benign prostatic hyperplasia
    Parnham, Arie
    Haq, Ahsanul
    JOURNAL OF CLINICAL UROLOGY, 2013, 6 (01) : 24 - 31
  • [43] Benign Prostatic Hyperplasia
    Kim, Choung Soo
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2007, 50 (07): : 626 - 636
  • [44] Histomorphological effects of the oil extract of Sphenocentrum jollyanum seed on benign prostatic hyperplasia induced by exogenous testosterone and estradiol in adult Wistar rats
    Mbaka, Godwin
    Ogbonnia, Steve
    Sulaiman, Adeol A.
    Osiagwu, Daniel
    AVICENNA JOURNAL OF PHYTOMEDICINE, 2019, 9 (01) : 21 - 33
  • [45] Effect of virgin coconut oil, lauric acid and myristic acid on serum and prostatic markers of benign prostatic hyperplasia
    Okorie, Claribel Chikwue
    Onyekwelu, Kenechukwu Chibuike
    Okorie, Chukwuemeka Ogueri
    Ikekpeazu, Joy Ebele
    Ezeagu, Edwin Ikechukwu
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2022, 21 (04) : 809 - 815
  • [46] Silodosin in the treatment of benign prostatic hyperplasia
    Rossi, Maxime
    Roumeguere, Thierry
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2010, 4 : 291 - 297
  • [47] Dutasteride for the treatment of benign prostatic hyperplasia
    Wu, Christopher
    Kapoor, Anil
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (10) : 1399 - 1408
  • [48] The prevention of benign prostatic hyperplasia (bph)
    Roper, W. G.
    MEDICAL HYPOTHESES, 2017, 100 : 4 - 9
  • [49] Endocrine control of benign prostatic hyperplasia
    La Vignera, S.
    Condorelli, R. A.
    Russo, G. I.
    Morgia, G.
    Calogero, A. E.
    ANDROLOGY, 2016, 4 (03) : 404 - 411
  • [50] Benign Prostatic Hyperplasia and Its Aetiologies
    Briganti, Alberto
    Capitanio, Umberto
    Suardi, Nazareno
    Gallina, Andrea
    Salonia, Andrea
    Bianchi, Marco
    Tutolo, Manuela
    Di Girolamo, Valerio
    Guazzoni, Giorgio
    Rigatti, Patrizio
    Montorsi, Francesco
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (13) : 865 - 871